@article{ZhangSharmaWeiheretal.2021,
  author    = {Ying Zhang and Amit Sharma and Hans Weiher and Matthias Schmid and Glen Kristiansen and Ingo G. H. Schmidt-Wolf},
  title     = {Clinical Studies on Cytokine-Induced Killer Cells: Lessons from Lymphoma Trials},
  series   = {Cancers},
  volume    = {13},
  number    = {23},
  publisher = {MDPI},
  address   = {Basel},
  issn      = {2072-6694},
  doi       = {10.3390/cancers13236007},
  url       = {https://nbn-resolving.org/urn:nbn:de:hbz:1044-opus-60290},
  year      = {2021},
  abstract  = {Cancer is a complex disease where resistance to therapies and relapses often pose a serious clinical challenge. The scenario is even more complicated when the cancer type itself is heterogeneous in nature, e.g., lymphoma, a cancer of the lymphocytes which constitutes more than 70 different subtypes. Indeed, the treatment options continue to expand in lymphomas. Herein, we provide insights into lymphoma-specific clinical trials based on cytokine-induced killer (CIK) cell therapy and other pre-clinical lymphoma models where CIK cells have been used along with other synergetic tumor-targeting immune modules to improve their therapeutic potential. From a broader perspective, we will highlight that CIK cell therapy has potential, and in this rapidly evolving landscape of cancer therapies its optimization (as a personalized therapeutic approach) will be beneficial in lymphomas.},
  language  = {en}
}